How medicine became geopolitics
In March 2020 a single notification from the Indian Directorate General of Foreign Trade restricted the export of paracetamol. Europe discovered it had no way to make its own.
We called it a supply chain problem. It was not. It was a sovereignty problem, and it had been building for thirty years while we were looking somewhere else.
A state that cannot manufacture its own active ingredients, sequence its own genomes or store its own health data does not control its health system. It rents it. And rent can be repriced, delayed or refused.
A state that cannot produce its own active ingredients does not have an independent health policy. It has a preference, subject to someone else's approval. The 2020 export restrictions were not a warning about logistics. They were a demonstration of where authority actually sits.
Population-scale sequencing has turned health data into a strategic asset. The countries building national genomic programmes are not doing it for science alone. Those that outsource both the data and the capacity to interpret it are making a constitutional decision without calling it one.
Whoever sets the regulatory standard decides who may sell, at what cost, and on whose timetable. This is soft power that never announces itself, and Europe spent two decades exercising it while failing to notice it was doing so.
Europe built the pharmaceutical industry and now debates resilience in committee rooms. Parts of the Gulf, importing almost everything a decade ago, are building sovereign genomic programmes, local manufacturing and national health data infrastructure — and moving faster, because they began without the burden of legacy assumptions.
Written for the people who have to answer when a minister asks what happens to patients if a single supplier stops shipping tomorrow. Ministry officials, sovereign investors, executives in pharmaceutical and biotechnology companies, and anyone building a health system rather than administering one.